New York State Common Retirement Fund Trims Stake in Grifols, S.A. (NASDAQ:GRFS)

New York State Common Retirement Fund decreased its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 20.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,629,272 shares of the biotechnology company’s stock after selling 429,014 shares during the period. New York State Common Retirement Fund owned 0.24% of Grifols worth $12,122,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in GRFS. R Squared Ltd purchased a new position in shares of Grifols during the 4th quarter worth $28,000. GAMMA Investing LLC lifted its holdings in shares of Grifols by 44.5% during the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,527 shares during the period. Signaturefd LLC grew its holdings in Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares during the period. Blue Trust Inc. grew its stake in shares of Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,970 shares during the period. Finally, HighTower Advisors LLC increased its holdings in shares of Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,546 shares during the last quarter.

Grifols Stock Performance

NASDAQ:GRFS opened at $7.43 on Tuesday. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $9.96. The stock has a market cap of $5.11 billion, a P/E ratio of 6.35 and a beta of 0.40. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The firm has a 50-day moving average of $7.37 and a two-hundred day moving average of $8.09.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GRFS. Morgan Stanley began coverage on Grifols in a report on Wednesday, February 12th. They set an “overweight” rating for the company. Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.